Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 455

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy

Open access
Sasportas, Laura S., Kasmieh, Randa, Wakimoto, Hiroaki, Hingtgen, Shawn, van de Water, Jeroen A. J. M., Mohapatra, Gayatry, Figueiredo, Jose Luiz, Martuza, Robert L., Weissleder, Ralph, Shah, Khalid · 2009 · Proceedings of the National Academy of Sciences

Abstract

The poor prognosis of patients with aggressive and invasive cancers combined with toxic effects and short half-life of currently available treatments necessitate development of more effective tumor selective therapies. Mesenchymal stem cells (MSCs) are emerging as novel cell-based delivery agents; however, a thorough investigation addressing their therapeutic potential and fate in different cancer models is lacking. In this study, we explored the engineering potential, fate, and therapeutic efficacy of human MSCs in a highly malignant and invasive model of glioblastoma. We show that engineered MSC retain their “stem-like” properties, survive longer in mice with gliomas than in the normal brain, and migrate extensively toward gliomas. We also show that MSCs are resistant to the cytokine tumor necrosis factor apoptosis ligand (TRAIL) and, when engineered to express secreted recombinant TRAIL, induce caspase-mediated apoptosis in established glioma cell lines as well as CD133-positive primary glioma cells in vitro. Using highly malignant and invasive human glioma models and employing real-time imaging with correlative neuropathology, we demonstrate that MSC-delivered recombinant TRAIL has profound anti-tumor effects in vivo. This study demonstrates the efficacy of diagnostic and therapeutic MSC in preclinical glioma models and forms the basis for developing stem cell-based therapies for different cancers.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.0806647106

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Research works printed but not linked: 4

  1. 10.1038/sj.mt.6300155 · doi:10.1038/sj.mt.6300155
  2. 10.1006/excr.1999.4760 · doi:10.1006/excr.1999.4760
  3. M Ehtesham, et al., Induction of glioblastoma apoptosis using neural stem cell-mediated delivery of tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res 62, 7170–7174 (2002).
  4. 10.3171/jns.2006.105.1.88 · doi:10.3171/jns.2006.105.1.88

Cited by

See all 455

Metadata

Authors
Sasportas, L. S., Kasmieh, R., Wakimoto, H., Hingtgen, S., van de Water, J. A. J. M., Mohapatra, G., Figueiredo, J. L., Martuza, R. L., Weissleder, R., & Shah, K.
Venue
Proceedings of the National Academy of Sciences
Published
2009-03-24
Volume
106
Issue
12
Pages
4822-4827
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W2000534793
Cited by
455
References
45
FWCI
17.51
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.